CME/CE QUIZ

Supplements and Featured Publications, Treatment and Management Options for Reversible Airway Disease, Volume 10, Issue 5 Suppl

CME/CE QUESTIONS

Continuing Medical Education Accreditation

The University of Cincinnati College of Medicine designates this educational activity for a maximum of 2 Category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those hours that he/she actually spends in the educational activity.

The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians.

Continuing Pharmacy Education Accreditation

Pharmacy Times

is approved by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEU) under the ACPE universal program number of 290-999-04-027-H01.

Instructions

After reading "Treatment and Management Options for Reversible Airway Disease," complete the program evaluation and select the 1 best answer to each of the following questions. A statement of continuing education hours will be mailed to those who successfully complete (a minimum score of 70%) the examination at the conclusion of the program.

1. Chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow obstruction that is often accompanied by:

  • Pansinusitis
  • Airway hyperreactivity

2. COPD is linked to several different systemic sequelae, including:

  • Chronic bronchitis and emphysema
  • Pneumonia and upper respiratory infections

3. In children the risk factors for asthma include female sex, upper respiratory infections, influenza, and low body weight.

  • False

4. Classification of asthma is based on:

  • Sex
  • Comorbid conditions

5. Those who are at most risk for exacerbations are:

  • COPD patients only
  • Patients with immune deficiencies only

6. First-line therapy for overall COPD and related exacerbations is:

  • Intravenous methylxanthines
  • Systemic glucocorticosteroid therapy

7. Short-acting ß2-agonists include:

  • Tiotropiam bromide
  • All of the above

8. According to the National Asthma Education and Prevention Program on the Global Initiative for Asthma, inpatient care exacerbations in asthma emphasize the use of inhaled short-acting ß2-agonists while systemic ß2-agonists should be considered only for very severe or nonresponsive cases.

  • False

9. The Global Initiative for Chronic Obstructive Lung Disease suggests the addition of systemic corticosteroids to bronchodilators for:

  • Moderate-to-severe COPD
  • Eupnea

10. Antibiotics are recommended for:

  • A viral infection
  • Dyspnea with purulent sputum

11. The prevalence of asthma has been rising in:

  • Men but not women
  • All groups

12. The S-isomer of albuterol:

  • Is responsible for all therapeutic benefits in asthma
  • Is metabolized faster than the R-isomer

13. Because levalbuterol is the pure R-isomer of a selective ß2-agonist, it causes:

  • No harmful effects on asthmatic symptoms, but dose-related effects on the heart
  • The same effects as an a-antagonist

14. Compared with equal doses of racemic albuterol, levalbuterol would be:

  • Less effective but safer
  • More effective but more likely to cause adverse effects

15. The cost effectiveness of levalbuterol compared with racemic albuterol has been shown in all of the following ways EXCEPT:

  • Shorter length of hospital stay
  • Lower overall cost of treatment

16. Healthcare expenditures for asthma and COPD are expected to decrease in the near future.

  • False

17. Which of the following are challenges that are faced by managed care organizations in the management and treatment of asthma and COPD?

  • Suboptimal or undertreatment of asthma and COPD patients
  • All of the above

18. Which of the following statements is FALSE?

  • During 1994-1996, 14.5 million missed work days occurred as a result of asthma complications
  • Treatment guidelines for asthma and COPD stratify treatment alternatives by disease severity

19. A tool used by managed care organizations to predict future patient outcomes when taking risk factors of disease progression into account is:

  • Standard outcome theory
  • Risk modeling

20. One of the major problems with clinical guidelines is that they are:

  • Often too complicated to implement into clinical practice
  • None of the above

For Pharmacists

ANSWER CARD INSTRUCTIONS

Testing and Grading Procedures

  • Each participant achieving a passing grade of 70% or higher on any examination will receive an official computer form stating the number of CE credits earned. This form should be safeguarded and may be used as documentation of credits earned.

Participants receiving a failing grade on any exam will be notified and permitted to take 1 reexamination at no cost.

  • All answers should be recorded on the answer form. Please print clearly to ensure receipt of CE credit.

Pharmacy Times

To receive credit certification electronically, please provide your e-mail address. Detach and mail completed exam form with your $10.00 payment to CE Department, 405 Glenn Drive, Suite 4, Sterling, VA 20164-4432; or fax to 703-404-1801.

  • Take the test online with a $5.00 payment at www.pharmacytimes. com and receive immediate grading and CE credits, and download your CE statement of credit.

Please photocopy the test form for additional test takers

Pharmacy Times

is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of 290-999-04-027-H01. The program is available for CE credit through July 31, 2005.

Answer card and evaluation form for Pharmacists follow on page S168.

CONTINUING EDUCATION

Treatment and Management Options for Reversible Airway Disease

GOAL

To provide participants with epidemiology and burden of illness of reversible airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), its costs, treatment options, and related managed care issues.

TARGET AUDIENCE

This activity is designed for physicians specializing in pulmonary medicine, allergy, and primary care; pharmacists; medical directors; pharmacy directors; group practice directors; hospital directors; home healthcare directors; and other managed care decision makers.

EDUCATIONAL OBJECTIVES

After completing this continuing education activity, the participant should be able to:

Describe the epidemiology, clinical and economic burden, and natural history of COPD and asthma.

  • Review the new therapeutic options available for the treatment of asthma and COPD.

Compare the cost effectiveness of levalbuterol versus racemic albuterol.

  • Discuss the impact of treating and managing asthma and COPD on managed care organizations.

CONTINUING MEDICAL EDUCATION ACCREDITATION

The University of Cincinnati College of Medicine designates this activity for a maximum of 2 Category 1 credits toward the AMA Physician's Recognition Award. Each physician should claim only those hours that he/she actually spends in the educational activity.

The University of Cincinnati College of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor medical education for physicians. Release Date: July 31, 2004. Expiration Date: July 31, 2005.

CONTINUING PHARMACY EDUCATION ACCREDITATION

Pharmacy Times

is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This program is approved for 2 contact hours (0.2 CEUs) under the ACPE universal program number of 290-999-04-027-H01. Release Date: July 31, 2004. Expiration Date: July 31, 2005.

FUNDING

This program is supported by an unrestricted educational grant from Sepracor.